Multiple Organ Failure and Refractory Cardiogenic Shock due to Venlafaxine Intoxication, Successfully Treated with Veno-Arterial Extracorporeal Life Support

Case Report

Austin Crit Care Case Rep. 2021; 5(1): 1021.

Multiple Organ Failure and Refractory Cardiogenic Shock due to Venlafaxine Intoxication, Successfully Treated with Veno-Arterial Extracorporeal Life Support

Le Balc’h P1, Painvin B1,3*, Gicquel T2,4 and Camus C1,3

1Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033 Rennes Cedex 9, France

2Laboratoire de Toxicologie Biologique et Médico-légale, Centre Hospitalier Universitaire Pontchaillou, 2 rue Henri le Guilloux, 35033 Rennes Cedex 9, France

3Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France

4Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolism and Cancer) Rennes, France

*Corresponding author: Painvin B, Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033 Rennes Cedex 9, France

Received: December 15, 2020; Accepted: January 23, 2021; Published: January 30, 2021

Abstract

Venlafaxine has critical side effects from arrhythmias to cardiogenic shock after toxic dose ingestion. We report a case of venlafaxine intoxication with Multiple Organ Failure (MOF) treated with Veno-Arterial Extracorporeal Life Support (VA-ECLS). A 60-year old male with a history of chronic depression ingested 72 tablets of prolonged-release venlafaxine hydrochloride 75 mg (total 5400 mg). Initial EKG showed broadened QRS complexes and Transthoracic Echocardiography (TTE) revealed diffuse ventricular hypokinesia with Left Ventricular Ejection Fraction (LVEF) of 15% for which dobutamine infusion was started. Due to persistent refractory cardiogenic shock and MOF, a Medos® Deltastream® VA-ECLS was surgically implanted in our intensive care unit. On day 1, toxicology analysis found plasma concentrations of venlafaxine 3.2mg/L and its metabolite desmethylvenlafaxine at 0.92 mg/L. At day 6, we performed a weaning trial, enabling ECLS removal. Motion defect of anteroseptal and inferolateral walls was also noticed. EKGs showed a shorten R wave in the anteroseptal territory leading to the potential diagnosis of underlying ischemic cardiomyopathy. The patient was extubated at day-10 and discharged for cardiology unit at day-17. At day-20, cardiac magnetic resonance imaging showed no sign of ischemia and TTE parameters were normalized. This is the first report of refractory cardiogenic shock and MOF due to venlafaxine intoxication treated with VA-ECLS. The main objective of ECLS is to restore cardiac output especially when ventricular failure is refractory to inotropes. Our experience suggests that MOF secondary to refractory cardiogenic shock should quickly prompt the implantation of a VA-ECLS in venlafaxine critical overdose.

Keywords: Cardiogenic Shock; Ecls; Intoxication; Venlafaxine; ICU

Introduction

Venlafaxine is a bicyclic antidepressant that inhibits neuronal uptake of norepinephrine, serotonin, and to a lesser extent, dopamine. It is one of the most prescribed drugs for depression, worldwide, and ranks as the seventh out of 25 most used anti-depressants for suicidal intention in the US [1]. Critical side effects from arrhythmias to cardiogenic shock can be seen following toxic dose ingestion [2], with variation in inter-individual susceptibility [3]. We report a case of venlafaxine intoxication with Multiple Organ Failure (MOF) treated with Veno-Arterial Extracorporeal Life Support (VA-ECLS).

Case Description

A 60-year old male with a history of chronic depression was treated with oral prolonged-release venlafaxine 75 mg/day, baclofen, and oxazepam. In June 2020, he ingested 72 tablets of prolongedrelease venlafaxine hydrochloride 75 mg (total of 5400 mg). Then, he was brought to a local hospital. On arrival, he developed ventricular tachycardia, which resolved spontaneously, and was intubated for respiratory failure. EKG showed broadened QRS complexes, Transthoracic Echocardiography (TTE) revealed diffuse ventricular hypokinesia with Left Ventricular Ejection Fraction (LVEF) of 15% for which dobutamine infusion was started.

The patient was referred to our unit for VA-ECLS evaluation. He presented with signs of hypoperfusion, anuria and liver failure with MAP of 62 mmHg while receiving dobutamine 15μg/kg/min. An EKG showed a non-significant ST elevation from V1 to V3 without mirroring. TTE revealed no Takotsubo cardiomyopathy but biventricular hypokinesia, LVEF of 10%, and low subaortic Velocity Time Integral (VTI) at 8cm. Due to persistent refractory cardiogenic shock and MOF, a Medos® Deltastream® VA-ECLS was surgically implanted in the right femoral triangle. Initial settings were Pump Motor Speed (PMS) 4010 revolutions per minute (rpm), resulting in a Blood Flow Rate (BFR) of 5.3 L/minute, sweep gas flow rate 4.5 L/minutes with oxygenator at 80%. Heat exchanger was set at 36°C. Initial characteristics and evolution are summarized in Table 1.

On day 1, toxicology analysis found plasma concentrations of: venlafaxine 3.2mg/L and its metabolite desmethylvenlafaxine 0.92 mg/L, baclofen 0.37mg/L, acetaminophen 6 mg/L, and oxazepam 0.3 mg/L.

Over the next days, ECLS setting remained: PMS at 3635 rpm (BRF 5.3L/min), oxygenator at 50% with a sweep gas flow rate of 3L/ min (Table 1). At day 6, we performed a weaning trial: BRF was set at 1 L/min for 1 hour. TTE then showed LVEF of 25%, with subaortic VTI at 16cm (Table 1) enabling ECLS removal. Motion defect of anteroseptal and inferolateral walls was also noticed. EKGs showed a shorten R wave in the anteroseptal territory leading to the potential diagnosis of underlying ischemic cardiomyopathy.

Citation:Le Balc’h P, Painvin B, Gicquel T and Camus C. Multiple Organ Failure and Refractory Cardiogenic Shock due to Venlafaxine Intoxication, Successfully Treated with Veno-Arterial Extracorporeal Life Support. Austin Crit Care Case Rep. 2021; 5(1): 1021.